Latest revenue
—
as of 2025-12-31
Latest net income
$-39.2M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think AEON is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $19.1M
- Enterprise value
- $85.3M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $1.45
- 52-wk low
- $0.63
- Beta
- —
- Shares out
- 26.3M
5-year trend
What this company does
Item 1. Business AEON is a biopharmaceutical company advancing its proprietary botulinum toxin complex ABP-450 as a biosimilar to Botox® (onabotulinumtoxinA) with the goal of achieving full-label United States (“U.S.”) market entry for debilitating medical conditions. On December 12, 2022, AEON Biopharma Sub, Inc. (formerly known as AEON Biopharma, Inc.) (“Old AEON”) and Priveterra Merger Sub, Inc., a wholly owned subsidiary of Priveterra Acquisition Corp. (“Priveterra”), a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more target…
AI summary unavailable — showing raw filing excerpt
Generated from AEON's filing dated 2026-03-30
Key risks
Item 1A. Risk Factors RISK FACTORS We are subject to various risks and uncertainties in the course of our business. You should carefully consider the risks and uncertainties described below and the other information in this report before making an investment in our Class A common stock, par value $0.0001 per share (“common stock”). Our business, financial condition, results of operations, or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common stock could decline and you could lose all or part of your investment. This report also contains forward-looking statements that involve risks and uncertainties. See…
AI summary unavailable — showing raw filing excerpt
Generated from AEON's filing dated 2026-03-30
Profitability
Return on equity
556.9%
98.5%Return on assets
-705.4%
152.8%Leverage
Debt / equity
-1.04×
96.6%Long-term debt / equity
-6.40×
Debt / assets
2335.9%
2159.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-11.8M | -229.7% | — |
Q4 2025 2025-12-31 | — | — | $-48.7M | -140.5% | — |
Q3 2025 2025-09-30 | — | — | $-2.1M | +66.2% | — |
Q2 2025 2025-06-30 | — | — | $2.5M | -94.7% | — |
Q1 2025 2025-03-31 | — | — | $9.1M | +107.7% | — |
Q4 2024 2024-12-31 | — | — | $120.1M | — | — |
Q3 2024 2024-09-30 | — | — | $-6.2M | — | — |
Q2 2024 2024-06-30 | — | — | $46.1M | +1269.2% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on AEON — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AEON
Institutional value
$163.0K
Total shares held
163.1K
Distinct holders
17
-5 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 90.5K | $89.2K | — | New |
| 2 | Formidable Asset Management, LLC | 20.0K | $22.0K | — | New |
| 3 | JANE STREET GROUP, LLC | 16.4K | $16.1K | — | New |
| 4 | VANGUARD FIDUCIARY TRUST CO | 14.7K | $14.5K | — | New |
| 5 | LPL Financial LLC | 11.5K | $11.3K | — | New |
| 6 | UBS Group AG | 4.2K | $4.1K | +130 (+3.2%) | Added |
| 7 | BlackRock, Inc. | 2.8K | $2.8K | +0 (+0.0%) | No change |
| 8 | Steward Partners Investment Advisory, LLC | 1.1K | $1.1K | +1.0K (+1000.0%) | Added |
| 9 | CITIGROUP INC | 742 | $731 | — | New |
| 10 | WOLFF WIESE MAGANA LLC | 567 | $559 | +0 (+0.0%) | No change |
| 11 | DUPONT CAPITAL MANAGEMENT CORP | 170 | $167 | +0 (+0.0%) | No change |
| 12 | SBI Securities Co., Ltd. | 105 | $103 | +0 (+0.0%) | No change |
| 13 | Vanguard Global Advisers, LLC | 102 | $100 | — | New |
| 14 | GHP Investment Advisors, Inc. | 95 | $94 | +0 (+0.0%) | No change |
| 15 | WELLS FARGO & COMPANY/MN | 90 | $89 | +0 (+0.0%) | No change |
| 16 | DANSKE BANK A/S | 1 | $1 | +0 (+0.0%) | No change |
| 17 | Caitong International Asset Management Co., Ltd | 1 | $1 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AEON's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.